Boost For Daiichi's Oncology Ambitions As AZ Agrees Huge $6.9bn Deal For Lead ADC Asset

AstraZeneca is paying $1.35bn upfront for global rights to a flagship Daiichi Sankyo oncology asset, in a deal potentially worth up to $6.9bn set to give a huge boost to the Japanese firm's ambitions in the sector.

Dividing breast cancer cell
AZ Strikes Major Deal For Daiichi Cancer ADC • Source: Shutterstock

In what should provide a massive fillip to Daiichi Sankyo Co. Ltd.'s ambitions to build its worldwide presence in oncology, AstraZeneca PLC has picked up global rights to one of the Japanese firm's lead development assets in the sector.

The massive deal will see the UK-based multinational pay $1.35bn upfront (half on execution, the remainder 12 months later), and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category